Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by Time4TAon May 27, 2011 8:55am
230 Views
Post# 18633417

VIVIMIND - Just Getting Started

VIVIMIND - Just Getting Started
Test Your Mind @ VIVIMIND.com
https://www.vivimind.com/
VIVIMIND™ is currently commercially available in Canada and Italy. BELLUS Health is actively seeking to expand VIVIMIND™’s commercial reach throughout the world via strategic partnerships. To that end, BELLUS recently formed exclusive distribution partnerships in Canada with Advanced Orthomolecular Research Inc., in Italy with FB Health Inc., and in the Middle East with the Agahan Group. BELLUS is currently in active partnership discussions with several parties for the rights to VIVIMIND™ in other territories.





Over $250 Million went into developing Alzhemed ( now Rebranded as VIVIMIND). Now being Marketed as a nutraceutical ...after all it is a Natural Product.  Marketed to healthy people as a “memory protection” therapy....just because of prior the refusal of the FDA to approve it means it doesn’t work.  Potential $1 Billion Dollar over the Counter therapy says its worth a chance IMO. I wouldn't ignore this market with an ever Aging population.The idea is to target VIVIMIND primarily at baby boomers, a population old enough to be concerned about age-related memory loss.There are 450 million baby boomers in the western world, so we’re playing into a market that’s huge and ready for it


There has never been a natural health product with the kind of scientific pedigree VIVIMIND has, data from 15 years of development and more than 2,000 people tested on the product.



Bellus CEO F. Bellini  is no Stranger to success. This is the same guy who was the Co-founder of BioChem Pharma Inc which was later sold to Shire Pharma Group of Britain for $5.9 Billion. He Personally made $180 million due to the Sale. This Guy has made his money....I think this product is being Marketed because he sees it is a great opportunity to service  a growing need for people who want and need the product



Bellus has the Product...it works and it cost $250 Million to Produce...and now it is being marketed as and Packaged as VIVIMIND pills.....Lets hope it takes hold just like the OMEGA 3 Craze did.


T4T






Bullboard Posts